Personalised cancer vaccine expected to be approved next year

A bespoke vaccine tailored to target an individual's unique skin cancer reduced rates of recurrence or death in a late-stage trial, making approval expected next year, according to the report. The finding is based on trial-stage evidence.

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.